Guerbet Announces Plans to Streamline Its Contrast Media Portfolio
July 10 2017 - 1:01AM
Villepinte (France), July 10, 2017 (7:00 AM CET) - Guerbet
(FR0000032526 GBT), the global specialist in contrast products and
solutions for medical imaging, announced today that it will phase
out sales throughout the world of two products: Hexabrix®
(meglumine and sodium ioxaglate) and Optimark®
(gadoversetamide).
Following the acquisition of Mallinckrodt's
contrast media & delivery systems business, Guerbet has taken
measures to streamline its brand portfolio.
In 2015, it announced the withdrawal in the US
of Hexabrix®, an iodinated contrast medium for X-ray imaging that
has the same indications as two other Guerbet products, Optiray®
(ioversol) and Xenetix® (iobitridol). Hexabrix® sales in Europe,
Asia and Latin America will progressively cease, by the end of 2019
at the latest. Guerbet's offer (Optiray® and Xenetix®) covers more
than 70 countries.
Similarly, Guerbet's decision to phase out
Optimark® is part of its product portfolio prioritization.
Optimark® and Dotarem® (gadoteric acid) are both gadolinium-based
contrast agents and have similar indications for MRI. Optimark® is
a linear agent and faces decreasing worldwide demand, while
Dotarem®, a macrocyclic and ionic agent, has seen worldwide demand
increase. Dotarem® is registered in more than 70 countries.
Sales of Optimark® will end first July 26, 2017
in European Union countries. Then, and in order to ensure a smooth
transition and continuous supply for patients, Optimark® phase out
will be progressively implemented in other geographic areas until
end of 2019.
This move to streamline its gadolinium-based
contrast agent portfolio through a focus on Dotarem® is consistent
with recent recommendations of the Pharmacovigilance Risk
Assessment Committee (PRAC) of
the European Medicines Agency (see July 7th, 2017
PRAC press release here).
"This rationalization will enable us to live up
to our undertaking to offer health professionals a complete range
of efficient and safe contrast media to improve diagnosis,
prognosis and quality of life for patients all over the world,
while ensuring our enhanced industrial and commercial efficiency",
says Guerbet CEO Yves L'Epine.
About Guerbet
Guerbet is a pioneer in the contrast agent field
with over 90 years' of experience and is one of the leaders in
medical imaging worldwide. It offers a full range of pharmaceutical
products, medical devices and services for X-ray (RX) and Magnetic
Resonance Imaging (MRI) scanners and Interventional Radiology and
Theranostics (IRT) to improve the diagnosis and treatment of
patients. With 7% of its revenue and more than 200 employees
dedicated to R&D, Guerbet invests heavily in research and
innovation. Guerbet (GBT) is listed on Euronext Paris (Segment B -
Mid Caps) and generated €776 million in revenue in 2016. For more
information about Guerbet, visit www.guerbet.com
Media Relations Contacts
Guerbet Global Alize RPCaroline Carmagnol & Wendy
Rigal+33 (0)1 44 54 36 66 / +33 (0)6 48 82 18 94guerbet@alizerp.com
|
Guerbet US Ted Deutsch(609)
578-8765ted@taftcommunications.com |
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/c988aa1a-eb27-4322-9213-d1223961cace
Guerbet (EU:GBT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Guerbet (EU:GBT)
Historical Stock Chart
From Jul 2023 to Jul 2024